| Bioactivity | HKI12134085 (compound 3) is an orally available nitrobenzothiazinone (BTZ) derivative with activity against Mycobacterium tuberculosis. HKI12134085 has in vivo inhibitory potency in a BALB/c mouse model of Mycobacterium tuberculosis infection[1]. |
| Name | HKI12134085 |
| CAS | 2102393-11-1 |
| Formula | C18H18F3N3O5S |
| Molar Mass | 445.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Joch M, et al. Whole cell hydride Meisenheimer complex biotransformation guided optimization of antimycobacterial benzothiazinones. Eur J Med Chem. 2024 Jan 15;264:116023. |
HKI12134085
CAS: 2102393-11-1 F: C18H18F3N3O5S W: 445.41
HKI12134085 (compound 3) is an orally available nitrobenzothiazinone (BTZ) derivative with activity against Mycobacteriu
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.